# IDOV-Immune for Advanced Solid Tumors

> **NCT06910657** · PHASE1 · RECRUITING · sponsor: **ViroMissile, Inc.** · enrollment: 78 (estimated)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer
- Melanoma
- Ovarian Cancer
- Gastric Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Breast Cancer
- Sarcoma
- Bladder Cancer
- Lung Cancer
- Prostate Cancer
- Cervical Cancers
- Head and Neck Cancers
- Adrenal Gland Tumors

## Interventions

- **BIOLOGICAL:** IDOV-Immune (oncolytic vaccinia virus)

## Key facts

- **NCT ID:** NCT06910657
- **Lead sponsor:** ViroMissile, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910657, "IDOV-Immune for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06910657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*